🇺🇸 FDA
Pipeline program

AK112, Cadonilimab, nab-paclitaxel, gemcitabine

AK112-210

Phase 2 small_molecule active

Quick answer

AK112, Cadonilimab, nab-paclitaxel, gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at Akeso with 1 ClinicalTrials.gov record(s).

Program details

Company
Akeso
Indication
Metastatic Pancreatic Ductal Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials